We address the problem of how COVID-19 deaths observed in an oncology clinical trial can be consistently taken into account in typical survival estimates. We refer to oncological patients since there is empirical evidence of strong correlation between COVID-19 and cancer deaths, which implies that COVID-19 deaths cannot be treated simply as non-informative censoring, a property usually required by the classical survival estimators. We consider the problem in the framework of the widely used Kaplan–Meier (KM) estimator. Through a counterfactual approach, an algorithmic method is developed allowing to include COVID-19 deaths in the observed data by mean-imputation. The procedure can be seen in the class of the Expectation-Maximization (EM) algorithms and will be referred to as Covid-Death Mean-Imputation (CoDMI) algorithm. We discuss the CoDMI underlying assumptions and the convergence issue. The algorithm provides a completed lifetime data set, where each Covid-death time is replaced by a point estimate of the corresponding virtual lifetime. This complete data set is naturally equipped with the corresponding KM survival function estimate and all available statistical tools can be applied to these data. However, mean-imputation requires an increased variance of the estimates. We then propose a natural extension of the classical Greenwood’s formula, thus obtaining expanded confidence intervals for the survival function estimate. To illustrate how the algorithm works, CoDMI is applied to real medical data extended by the addition of artificial Covid-death observations. The results are compared with the estimates provided by the two naïve approaches which count COVID-19 deaths as censoring or as deaths by the disease under study. In order to evaluate the predictive performances of CoDMI an extensive simulation study is carried out. The results indicate that in the simulated scenarios CoDMI is roughly unbiased and outperforms the estimates obtained by the naïve approaches. A user-friendly version of CoDMI programmed in R is freely available.
[1]
F. Moriconi,et al.
COVID-19 and Cancer: Implications for Survival Analysis
,
2021,
Annals of Surgical Oncology.
[2]
K. Rufibach,et al.
Assessing the Impact of COVID-19 on the Clinical Trial Objective and Analysis of Oncology Clinical Trials—Application of the Estimand Framework
,
2020,
Statistics in biopharmaceutical research.
[3]
Alokkumar Jha,et al.
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
,
2020,
The Lancet.
[4]
K. Yuen,et al.
Clinical Characteristics of Coronavirus Disease 2019 in China
,
2020,
The New England journal of medicine.
[5]
P. Shen,et al.
Aalen's linear model for doubly censored data
,
2018,
Statistics.
[6]
M. V. van Noorden,et al.
Correcting for dependent censoring in routine outcome monitoring data by applying the inverse probability censoring weighted estimator
,
2018,
Statistical methods in medical research.
[7]
Trevor Hastie,et al.
Computer Age Statistical Inference: Algorithms, Evidence, and Data Science
,
2016
.
[8]
J. Pearl,et al.
Causal Inference in Statistics: A Primer
,
2016
.
[9]
A. Legedza,et al.
An Overview of Practical Approaches for Handling Missing Data in Clinical Trials
,
2009,
Journal of biopharmaceutical statistics.
[10]
J. Kalbfleisch,et al.
The Statistical Analysis of Failure Time Data: Kalbfleisch/The Statistical
,
2002
.
[11]
W. Shih,et al.
Current Controlled Trials in Cardiovascular Medicine
,
2002
.
[12]
R. Gray.
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
,
1988
.
[13]
D. Rubin,et al.
Maximum likelihood from incomplete data via the EM - algorithm plus discussions on the paper
,
1977
.
[14]
B. Efron.
The two sample problem with censored data
,
1967
.
[15]
E. Kaplan,et al.
Nonparametric Estimation from Incomplete Observations
,
1958
.